1. Home
  2. NEXR vs DRMA Comparison

NEXR vs DRMA Comparison

Compare NEXR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NEXR

Nexera Technologies Ltd Ordinary Shares

N/A

Current Price

$0.47

Market Cap

4.2M

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.32

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXR
DRMA
Founded
N/A
2014
Country
Israel
United States
Employees
38
9
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2M
5.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
NEXR
DRMA
Price
$0.47
$1.32
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
18.1M
92.8K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.64
52 Week High
$1.28
$7.33

Technical Indicators

Market Signals
Indicator
NEXR
DRMA
Relative Strength Index (RSI) 43.10 50.06
Support Level N/A $1.13
Resistance Level $1.28 $1.40
Average True Range (ATR) 0.14 0.13
MACD -0.03 0.01
Stochastic Oscillator 3.33 34.31

Price Performance

Historical Comparison
NEXR
DRMA

About NEXR Nexera Technologies Ltd Ordinary Shares

Nexera Technologies Ltd focuses on homeland security technologies, artificial intelligence-driven solutions, and detection systems through its subsidiaries and strategic collaborations. The company collaborates with technology partners to distribute and promote new systems such as 3D imaging and electromagnetic threat detection tools, autonomous security technologies, and multi-layered security ecosystems for critical infrastructure and high-traffic venues.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: